<DOC>
	<DOCNO>NCT00058006</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . The use celecoxib may effective way prevent recurrence stage I stage II head neck cancer stage I non-small cell lung cancer . PURPOSE : This randomized phase II trial study celecoxib see well work compare placebo prevent disease recurrence patient stage I stage II head neck cancer stage I non-small cell lung cancer .</brief_summary>
	<brief_title>Celecoxib Treating Patients With Early-Stage Head Neck Cancer Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare rate new malignancy ( recurrence second primary tumor ) patient early-stage head neck cancer non-small cell lung cancer treat celecoxib v placebo . - Compare event-free overall survival patient treat drug v placebo . - Determine toxic effect associate long-term use celecoxib patient . - Correlate cyclooxygenase-2 transforming growth factor ( TGF ) -beta expression CYP2C9 TGF-beta genotype rate new malignancy survival patient treat drug v placebo . OUTLINE : This randomize , placebo-controlled , double-blind , multicenter study . Patients stratify accord smoke history ( active smoker [ include quit within 1 year diagnosis ] v former smoker vs non-smokers ) , tumor type ( lung cancer v head neck cancer ) , stage ( I vs II head neck cancer T1 v T2 lung cancer ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral celecoxib twice daily . - Arm II : Patients receive oral placebo twice daily . In arm , treatment continue 24 month absence disease recurrence unacceptable toxicity . Patients follow every 6 month 5 year disease recurrence . PROJECTED ACCRUAL : A total 121 patient ( approximately 60 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow histologically confirm diagnosis : Stage I nonsmall cell lung cancer ( NSCLC ) No small cell component Stage III squamous cell cancer head neck No WHO type II III nasopharyngeal cancer No sinonasal undifferentiated carcinoma No evidence disease Must undergone surgery radiotherapy curative intent within past 424 week PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Platelet count least 50,000/mm^3 Hepatic Bilirubin normal AST/ALT great 2 time upper limit normal Renal Creatinine great 2.0 mg/dL Cardiovascular No uncontrolled hypertension No severe congestive heart failure Pulmonary No history asthma cause cyclooxygenase2 ( COX2 ) inhibitor , nonsteroidal antiinflammatory drug ( NSAIDs ) , salicylates , sulfonamides Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No prior malignancy ( include skin cancer situ malignancy ) No diagnosis peptic ulcer disease gastritis/esophagitis within past 60 day No prior hypersensitivity reaction COX2 inhibitor , NSAIDs , salicylates , sulfonamides No concurrent medical condition would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy No cumulative oral IV corticosteroid use total 2 week within past 3 month No concurrent oral steroid 2 consecutive week Concurrent inhale steroid allow Radiotherapy See Disease Characteristics No prior definitive radiotherapy stage I NSCLC Surgery See Disease Characteristics Prior pneumonectomy lobectomy mediastinal lymph node sample dissection stage I NSCLC allow No prior segmentectomies wedge resection stage I NSCLC Other More 60 day since prior treatment peptic ulcer disease gastritis/esophagitis No prior NSAID use within past 30 day frequency 3 time week 2 week No concurrent NSAIDs ( include lowdose aspirin ) No concurrent COX2 inhibitors No concurrent fluconazole No concurrent lithium</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage I squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage I squamous cell carcinoma larynx</keyword>
	<keyword>stage I squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage I squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage I squamous cell carcinoma oropharynx</keyword>
	<keyword>stage I squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage II squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage II squamous cell carcinoma larynx</keyword>
	<keyword>stage II squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage II squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage II squamous cell carcinoma oropharynx</keyword>
	<keyword>stage II squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>salivary gland squamous cell carcinoma</keyword>
	<keyword>stage I salivary gland cancer</keyword>
	<keyword>stage II salivary gland cancer</keyword>
</DOC>